Hemoglobin stability impact on healthcare resource utilization and costs among dialysis-dependent patients with anemia of end-stage kidney disease | BMC Nephrology

USRDS annual data report: Epidemiology of kidney disease in the United States. 2023. Accessed 12 March 2025.

Cappellini MD, Motta I. Anemia in clinical practice-definition and classification: Does hemoglobin change with aging? Semin Hematol. 2015;52(4):261–9.

PubMed 

Google Scholar 

KDIGO. Clinical practice guideline for anemia in chronic kidney disease. Kidney Int. 2012;2(4):279–335.

Google Scholar 

Singh AK, Carroll K, Perkovic V, Solomon S, Jha V, Johansen KL, Lopes RD, Macdougall IC, Obrador GT, Waikar SS, et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. N Engl J Med. 2021;385(25):2325–35.

PubMed 
CAS 

Google Scholar 

Barratt J, Andric B, Tataradze A, Schömig M, Reusch M, Valluri U, Mariat C. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: A phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transpl. 2021;36(9):1616–28.

CAS 

Google Scholar 

Eckardt K-U, Agarwal R, Aswad A, Awad A, Block GA, Bacci MR, Farag YMK, Fishbane S, Hubert H, Jardine A, et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. N Engl J Med. 2021;384(17):1601–12.

PubMed 
CAS 

Google Scholar 

Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23(10):1631–34.

PubMed 
PubMed Central 
CAS 

Google Scholar 

Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005;68(3):1337–43.

PubMed 
CAS 

Google Scholar 

Gilbertson DT, Peng Y, Bradbury B, Ebben JP, Collins AJ. Hemoglobin level variability: Anemia management among variability groups. Am J Nephrol. 2009;30(6):491–98.

PubMed 
CAS 

Google Scholar 

Zhao L, Hu C, Cheng J, Zhang P, Jiang H, Chen J. Haemoglobin variability and all-cause mortality in haemodialysis patients: A systematic review and meta-analysis. Nephrol (Carlton). 2019;24(12):1265–72.

Google Scholar 

KDOQI. Clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50(3):471–530.

Google Scholar 

Drüeke TB, Locatelli F, Clyne N, Eckardt K-U, Macdougall IC, Tsakiris D, Burger H-U, Scherhag A. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071–84.

PubMed 

Google Scholar 

Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. New Engl J Med. 2006;355(20):2085–98.

PubMed 
CAS 

Google Scholar 

Bello NA, Lewis EF, Desai AS, Anand IS, Krum H, McMurray JJ, Olson K, Solomon SD, Swedberg K, van Veldhuisen Dj, et al. Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. Eur J Heart Fail. 2015;17(11):1201–07.

PubMed 
CAS 

Google Scholar 

Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9):584–90.

PubMed 
CAS 

Google Scholar 

Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019–32.

PubMed 

Google Scholar 

Lacson E Jr., Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis. 2003;41(1):111–24.

PubMed 

Google Scholar 

Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol. 2006;1(6):1205–10.

PubMed 

Google Scholar 

Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol. 2007;18(12):3164–70.

PubMed 
CAS 

Google Scholar 

Brunelli SM, Lynch KE, Ankers ED, Joffe MM, Yang W, Thadhani RI, Feldman HI. Association of hemoglobin variability and mortality among contemporary incident hemodialysis patients. Clin J Am Soc Nephrol. 2008;3(6):1733–40.

PubMed 
PubMed Central 
CAS 

Google Scholar 

Ishani A, Solid CA, Weinhandl ED, Gilbertson DT, Foley RN, Collins AJ. Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death. Nephrol Dial Transpl. 2008;23(5):1682–89.

Google Scholar 

Handelman GJ, Kotanko P, Cisternas MG, Hoenich N, Usvyat L, Kuhlmann M, Levin NW. Hospitalization and mortality in hemodialysis patients: Association with hemoglobin variability. Blood Purif. 2013;35(4):247–57.

PubMed 
CAS 

Google Scholar 

Moreno F, Sanz-Guajardo D, López-Gómez JM, Jofre R, Valderrábano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish cooperative renal patients quality of life study group of the Spanish society of nephrology. J Am Soc Nephrol. 2000;11(2):335–42.

PubMed 

Google Scholar 

Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int. 2003;63(5):1908–14.

PubMed 

Google Scholar 

Jain M, Shah M, Thakker KM, Rava A, Block AP, Ndiba-Markey C, Pinto L. Estimating prevalence of classical homocystinuria in the United States using Optum’s de-identified market clarity data. Mol Genet Metab Rep. 2024;40:101101.

PubMed 
PubMed Central 
CAS 

Google Scholar 

Kanda E, Rastogi A, Murohara T, Lesén E, Agiro A, Arnold M, Chen G, Yajima T, Järbrink K, Pollack CV Jr. Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia. BMC Nephrol. 2023;24(1):18.

PubMed 
PubMed Central 
CAS 

Google Scholar 

Vivekanand J, Johansen KL, Pergola PE, Coyne DW, St. Ledger K, M S, Bhatt PR, Duarte ME, Singh AK. Hemoglobin stability in the ASCEND-D and -ND trials. J Am Soc Nephrol. 2022;33:244.

Strippoli GF, Craig JC, Manno C, Schena FP. Hemoglobin targets for the anemia of chronic kidney disease: A meta-analysis of randomized, controlled trials. J Am Soc Nephrol. 2004;15(12):3154–65.

PubMed 

Google Scholar 

Dasgupta I, Bagnis CI, Floris M, Furuland H, Zurro DG, Gesualdo L, Heirman N, Minutolo R, Pani A, Portolés J, et al. Anaemia and quality of life in chronic kidney disease: A consensus document from the European anaemia of CKD Alliance. Clin Kidney J. 2024;17(8):sfae205.

PubMed 
PubMed Central 
CAS 

Google Scholar 

Fuertinger DH, Wang LC, Jörg DJ, Rivera Fuentes L, Ye X, Casper S, Zhang H, Mermelstein A, Cherif A, Ho K, et al. Effects of individualized anemia therapy on hemoglobin stability: A randomized controlled pilot trial in patients on hemodialysis. Clin J Am Soc Nephrol. 2024;1138–47.

Medicare advantage in 2024: Enrollment update and key trends. Accessed 12 March 2025.